Constructing a better binding peptide for drug delivery targeting the interleukin-4 receptor

References

• Mathew M, Verma RS. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy. Cancer Sci. 2009;100(8):1359–1365.
   PubMed Web of Science ®Google Scholar
• Chistiakov DA, Chekhonin IV, Chekhonin VP. The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme. Eur J Pharmacol. 2017;810:70–82.
   PubMed Web of Science ®Google Scholar
• Megan G, Kelly CM, Andrea C. HER2: an emerging target in colorectal cancer. Curr Probl Cancer. 2018;42(6):560–571.
   PubMed Web of Science ®Google Scholar
• Shibuya M. VEGF-VEGFR system as a target for suppressing inflammation and other diseases. Endocr Metab Immune Disord Drug Targets. 2015;15(2):135–144.
   PubMed Web of Science ®Google Scholar
• Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366(1):2–16.
   PubMed Web of Science ®Google Scholar
• Chi L, Na MH, Jung HK, et al. Enhanced delivery of liposomes to lung tumor through targeting interleukin-4 receptor on both tumor cells and tumor endothelial cells. J Control Release. 2015;209:327–336.
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–742.
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–246.
   PubMed Web of Science ®Google Scholar
• Chong CR, Janne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med. 2013;19(11):1389–1400.
   PubMed Web of Science ®Google Scholar
• Susumu K, Boggon TJ, Tajhal D, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352(8):786–792.
   PubMed Web of Science ®Google Scholar
• Guruprasath P, Kim J, Gunassekaran GR, et al. Interleukin-4 receptor-targeted delivery of Bcl-xL siRNA sensitizes tumors to chemotherapy and inhibits tumor growth. Biomaterials. 2017;142:101–111.
   PubMed Web of Science ®Google Scholar
• Natoli A, Lupertz R, Merz C, et al. Targeting the IL-4/IL-13 signaling pathway sensitizes Hodgkin lymphoma cells to chemotherapeutic drugs. Int J Cancer. 2013;133(8):1945–1954.
   PubMed Web of Science ®Google Scholar
• Joshi BH, Leland P, Lababidi S, et al. Interleukin-4 receptor alpha overexpression in human bladder cancer correlates with the pathological grade and stage of the disease. Cancer Med. 2014;3(6):1615–1628.
   PubMed Web of Science ®Google Scholar
• Mueller TD, Zhang JL, Sebald W, et al. Structure, binding, and antagonists in the IL-4/IL-13 receptor system. Biochim Biophys Acta. 2002;1592(3):237–250.
   PubMed Web of Science ®Google Scholar
• Kawakami M, Kawakami K, Stepensky VA, et al. Interleukin 4 receptor on human lung cancer: a molecular target for cytotoxin therapy. Clin Cancer Res. 2002;8(11):3503–3511.
   PubMed Web of Science ®Google Scholar
• Venmar KT, Carter KJ, Hwang DG, et al. IL4 receptor ILR4alpha regulates metastatic colonization by mammary tumors through multiple signaling pathways. Cancer Res. 2014;74(16):4329–4340.
   PubMed Web of Science ®Google Scholar
• Todaro M, Lombardo Y, Francipane MG, et al. Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. Cell Death Differ. 2008;15(4):762–772.
   PubMed Web of Science ®Google Scholar
• Todaro M, Alea MP, Di Stefano AB, et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell. 2007;1(4):389–402.
   PubMed Web of Science ®Google Scholar
• Conticello C, Pedini F, Zeuner A, et al. IL-4 protects tumor cells from anti-cd95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins. J Immunol. 2004;172(9):5467–5477.
   PubMed Web of Science ®Google Scholar
• Surana R, Wang S, Xu W, et al. IL4 limits the efficacy of tumor-targeted antibody therapy in a murine model. Cancer Immunol Res. 2014;2(11):1103–1112.
   PubMed Web of Science ®Google Scholar
• Kawakami K, Kawakami M, Puri RK. Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy. Crit Rev Immunol. 2001;21(1–3):299–310.
   PubMed Web of Science ®Google Scholar
• Rand RW, Kreitman RJ, Patronas N, et al. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res. 2000;6(6):2157–2165.
   PubMed Web of Science ®Google Scholar
• Koji K, Kawakami M, Husain SR, et al. Targeting interleukin-4 receptors for effective pancreatic cancer therapy. Cancer Res. 2002;62(13):3575.
   PubMed Web of Science ®Google Scholar
• Weber F, Asher A, Bucholz R, et al. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neuro Oncol. 2003;64(1–2):125–137.
   PubMed Web of Science ®Google Scholar
• Garland L, Gitlitz B, Ebbinghaus S, et al. Phase I trial of intravenous IL-4 pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor. J Immunother. 2005;28(4):376–381.
   PubMed Web of Science ®Google Scholar
• Yang L, Horibe T, Kohno M, et al. Targeting interleukin-4 receptor alpha with hybrid peptide for effective cancer therapy. Mol Cancer Ther. 2012;11(1):235–243.
   PubMed Web of Science ®Google Scholar
• Ishige K, Shoda J, Kawamoto T, et al. Potent in vitro and in vivo antitumor activity of interleukin-4-conjugated Pseudomonas exotoxin against human biliary tract carcinoma. Int J Cancer. 2008;123(12):2915–2922.
   PubMed Web of Science ®Google Scholar
• Guo C, Ouyang Y, Cai J, et al. High expression of IL-4R enhances proliferation and invasion of hepatocellular carcinoma cells. Int J Biol Markers. 2017;32(4):384–390.
   Web of Science ®Google Scholar
• Liu R, Li X, Xiao W, et al. Tumor-targeting peptides from combinatorial libraries. Adv Drug Deliv Rev. 2017;110–111:13–37.
   PubMed Web of Science ®Google Scholar
• Seto K, Shoda J, Horibe T, et al. Targeting interleukin-4 receptor alpha by hybrid peptide for novel biliary tract cancer therapy. Int J Hepatol. 2014;2014:1–7.
   Google Scholar
• Mei H, Hu Y, Wang H, et al. Binding of EGF1 domain peptide in coagulation factor VII with tissue factor and its implications for the triggering of coagulation. J Huazhong Univ Sci Technol [Med Sci]. 2010;30(1):42–47.
   PubMedGoogle Scholar
• Chen H, Niu X, Gao A, et al. Mitochondrial signal peptide guides EGFP-GRP75 fusion proteins into mitochondria. Chin J Cell Mol Immunol. 2016;32(10):1311–1316.
   Google Scholar
• Cao XW, Yang XZ, Du X, et al. Structure optimization to improve the delivery efficiency and cell selectivity of a tumor-targeting cell-penetrating peptide. J Drug Target. 2018;26(9):1–28.
   PubMed Web of Science ®Google Scholar
• Shin MC, Min KA, Cheong H, et al. Tandem-multimeric F3-gelonin fusion toxins for enhanced anti-cancer activity for prostate cancer treatment. Int J Pharm. 2017;524(1–2):101–110.
   PubMed Web of Science ®Google Scholar
• Lee S, Xie J, Chen X. Peptides and peptide hormones for molecular imaging and disease diagnosis. Chem Rev. 2010;110(5):3087–3111.
   PubMed Web of Science ®Google Scholar
• Lin B, Yang XZ, Cao XW, et al. A novel trichosanthin fusion protein with increased cytotoxicity to tumor cells. Biotechnol Lett. 2017;39(1):71–78.
   PubMed Web of Science ®Google Scholar
• Song S, Liu D, Peng J, et al. Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int J Pharm. 2008;363(1–2):155–161.
   PubMed Web of Science ®Google Scholar
• Ren H, Gao C, Zhou L, et al. EGFR-targeted poly (ethylene glycol)-distearoylphosphatidylethanolamine micelle loaded with paclitaxel for laryngeal cancer: preparation, characterization and in vitro evaluation. Drug Deliv. 2015;22(6):785–794.
   PubMed Web of Science ®Google Scholar
• Fan M, Liang X, Yang D, et al. Epidermal growth factor receptor-targeted peptide conjugated phospholipid micelles for doxorubicin delivery. J Drug Target. 2016;24(2):111–119.
   PubMed Web of Science ®Google Scholar
• Li Z, Zhao R, Wu X, et al. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J. 2005;19(14):1978–1985.
   PubMed Web of Science ®Google Scholar
• Kohno M, Horibe T, Haramoto M, et al. A novel hybrid peptide targeting EGFR-expressing cancers. Eur J Cancer. 2011;47(5):773–783.
   PubMed Web of Science ®Google Scholar